Edition:
United Kingdom

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

8.07USD
4:50pm GMT
Change (% chg)

$0.01 (+0.12%)
Prev Close
$8.06
Open
$8.12
Day's High
$8.20
Day's Low
$8.01
Volume
26,681
Avg. Vol
62,765
52-wk High
$27.77
52-wk Low
$7.20

Select another date:

Mon, Dec 4 2017

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2A6uuro) Further company coverage:

BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56

* Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

* RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495

* Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh

Select another date: